As millions of adults worldwide use GLP-1 and dual GLP-1/GIP receptor agonists, an expert consensus from three major European health organizations clarifies that the dramatic weight loss these drugs produce is not without meaningful biological and psychological costs—costs that require active clinical management rather than passive monitoring.
The consensus, developed jointly by the European Association for the Study of Obesity, the European Federation of the Associations of Dietitians, and the European Council for Cardiovascular Prevention and Oncology, synthesizes evidence across three domains where incretin-based therapies create underappreciated risks. On the nutritional side, rapid appetite suppression and gastrointestinal side effects can compromise dietary quality, protein adequacy, and micronutrient sufficiency—particularly for vitamins and minerals that depend on consistent food volume and variety. The statement identifies protein preservation during weight loss as a priority target, coupling adequate intake with progressive resistance exercise to defend fat-free mass. Psychologically, the drugs alter food reward circuitry in ways that may disrupt longstanding coping mechanisms tied to eating, erode social bonds built around food, and create identity challenges for individuals whose relationship with food changes abruptly—prompting a recommendation for proactive psychological screening and integrated behavioral support.
This consensus arrives at a critical inflection point. GLP-1 receptor agonists were initially validated in trials focused on glycemic and cardiovascular endpoints; the nutritional and functional consequences of sustained use were largely secondary considerations. The growing body of evidence now shows that lean mass losses during GLP-1-driven weight reduction can parallel or exceed those seen with caloric restriction alone—a pattern with long-term implications for metabolic rate, physical function, and frailty risk, especially in older adults. The consensus is pragmatic rather than prescriptive, which reflects genuine uncertainty in the evidence base: specific protein thresholds and monitoring intervals are proposed as guidance, not as rigorously validated protocols. For clinicians, the core message is structural—successful incretin therapy increasingly requires a multidisciplinary team integrating dietetic, exercise, and psychological support rather than pharmacologic management alone.
